# MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

> **NCT05903092** · PHASE2 · RECRUITING · sponsor: **Hirva Mamdani** · enrollment: 84 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- SCLC
- Extensive Stage Small Cell Lung Cancer
- Limited Stage Small-Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Monalizumab
- **DRUG:** Carboplatin or Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT05903092
- **Lead sponsor:** Hirva Mamdani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2029-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903092, "MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05903092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*